A citation-based method for searching scientific literature

Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi, Atsuhiko Sato, Shoji Kudoh. Am J Respir Crit Care Med 2005
Times Cited: 631







List of co-cited articles
671 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
56

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
630
55

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
55

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
46

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
46

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
669
38

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
24

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
599
23

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
930
22

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
20

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
932
18

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
113
17

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
549
16

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
229
15

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Hisashi Oku, Toshikatsu Shimizu, Tomoji Kawabata, Morio Nagira, Ichiro Hikita, Azumi Ueyama, Shuuichi Matsushima, Mikinori Torii, Akinori Arimura. Eur J Pharmacol 2008
275
14

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
13

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
594
13

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Brett Ley, Jeffrey Swigris, Bann-Mo Day, John L Stauffer, Karina Raimundo, Willis Chou, Harold R Collard. Am J Respir Crit Care Med 2017
91
14

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
575
13

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
J W Song, S-B Hong, C-M Lim, Y Koh, D S Kim. Eur Respir J 2011
448
12

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
117
12

Idiopathic pulmonary fibrosis.
Fernando J Martinez, Harold R Collard, Annie Pardo, Ganesh Raghu, Luca Richeldi, Moises Selman, Jeffrey J Swigris, Hiroyuki Taniguchi, Athol U Wells. Nat Rev Dis Primers 2017
390
12

Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.
Motoki Natsuizaka, Hirofumi Chiba, Koji Kuronuma, Mitsuo Otsuka, Kazumi Kudo, Mitsuru Mori, Masashi Bando, Yukihiko Sugiyama, Hiroki Takahashi. Am J Respir Crit Care Med 2014
241
12

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
328
12

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
483
12


Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
225
11

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
201
11

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Ulrich Costabel, Carlo Albera, Lisa H Lancaster, Chin-Yu Lin, Philip Hormel, Henry N Hulter, Paul W Noble. Respiration 2017
76
13

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Fernando J Martinez, Joao A de Andrade, Kevin J Anstrom, Talmadge E King, Ganesh Raghu. N Engl J Med 2014
303
10

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients.
Hui Huang, Hua Ping Dai, Jian Kang, Bao Yuan Chen, Tie Ying Sun, Zuo Jun Xu. Medicine (Baltimore) 2015
23
43

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
158
10

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Ganesh Raghu, Bernt van den Blink, Mark J Hamblin, A Whitney Brown, Jeffrey A Golden, Lawrence A Ho, Marlies S Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E Antin-Ozerkis,[...]. JAMA 2018
98
10

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
142
10

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Kenneth F Glasscock,[...]. Thorax 2016
102
9

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Carlo Albera, Ulrich Costabel, Elizabeth A Fagan, Marilyn K Glassberg, Eduard Gorina, Lisa Lancaster, David J Lederer, Steven D Nathan, Dominique Spirig, Jeff J Swigris. Eur Respir J 2016
94
9

Antifibrotic activities of pirfenidone in animal models.
C J Schaefer, D W Ruhrmund, L Pan, S D Seiwert, K Kossen. Eur Respir Rev 2011
263
9

High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Maurits Demedts, Juergen Behr, Roland Buhl, Ulrich Costabel, Richard Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, François Laurent,[...]. N Engl J Med 2005
654
9

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, Maria L Padilla, Carlo Albera, Steven D Nathan, Marlies S Wijsenbeek, John L Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel. Eur Respir Rev 2017
75
12

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
88
10

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
393
9

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Ryo Okuda, Eri Hagiwara, Tomohisa Baba, Hideya Kitamura, Terufumi Kato, Takashi Ogura. Respir Med 2013
71
11

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
S Harari, A Caminati, C Albera, C Vancheri, V Poletti, A Pesci, F Luppi, C Saltini, C Agostini, E Bargagli,[...]. Respir Med 2015
57
14

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
641
8


Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
Harold R Collard, Talmadge E King, Becki Bucher Bartelson, Jason S Vourlekis, Marvin I Schwarz, Kevin K Brown. Am J Respir Crit Care Med 2003
501
8

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Ute Oltmanns, Nicolas Kahn, Karin Palmowski, Annette Träger, Heinrich Wenz, Claus Peter Heussel, Philipp A Schnabel, Michael Puderbach, Matthias Wiebel, Svenja Ehlers-Tenenbaum,[...]. Respiration 2014
68
11

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Ganesh Raghu, Juergen Behr, Kevin K Brown, Jim J Egan, Steven M Kawut, Kevin R Flaherty, Fernando J Martinez, Steven D Nathan, Athol U Wells, Harold R Collard,[...]. Ann Intern Med 2013
305
8

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida,[...]. Eur Respir J 2015
116
8

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
Talmadge E King, Jürgen Behr, Kevin K Brown, Roland M du Bois, Lisa Lancaster, Joao A de Andrade, Gerd Stähler, Isabelle Leconte, Sébastien Roux, Ganesh Raghu. Am J Respir Crit Care Med 2008
374
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.